RegenXBio (RGNX) has shared an update.
REGENXBIO Inc. has announced a significant leadership change with Kenneth T. Mills stepping down as President and CEO but taking on the role of Chairman of the Board and remaining as an advisor until mid-2025. Curran M. Simpson will succeed Mills as the new CEO, starting July 1, 2024, bringing extensive experience from his prior roles in the life sciences industry. Simpson’s compensation includes a $610,000 base salary and a potential annual bonus, alongside a substantial equity award. Daniel Tassé will become the new Lead Independent Director, and the company has maintained its financial and operational outlook.
See more data about RGNX stock on TipRanks’ Stock Analysis page.
